Business & Industry
Business & Industry
Innovent-Lilly Partnership Expands Global Drug Development
Innovent Biologics has announced a strategic Innovent-Lilly partnership with Eli Lilly and Company to advance the global development of new medicines in oncology and immunology. The agreement represents the seventh partnership between the two companies and introduces a new...
Business & Industry
Drug Device Combination Products Driving Delivery Precision
Deep dive into the convergence of medical engineering and pharmaceutical science, focusing on how integrated delivery systems enhance dosing accuracy and patient outcomes.
Business & Industry
GSK Targets Faster Drug Development, Selective Acquisitions
GSK’s new chief executive, Luke Miels, said the drugmaker will prioritise faster drug development as it enters its next phase of growth, with a tighter focus on programmes that can change standards of care and selective bolt-on acquisitions. Miels,...
Business & Industry
Sustainable Materials in Pharmaceutical Drug Delivery Systems
Examination of the pharmaceutical industry's transition toward biodegradable polymers and eco-friendly excipients to reduce environmental impact while maintaining high therapeutic standards.
Business & Industry
UK and Japan Strengthen Science and Technology Ties by £33bn
The UK and Japanese governments have announced a wide-ranging partnership that sees UK and Japan strengthen science and technology ties across pharmaceuticals, genomics, quantum computing and advanced manufacturing. The agreement was confirmed during a visit to Japan by the...
Business & Industry
Halo Pharma Emerges as the North American Drug Product CDMO
Halo Pharma becomes dedicated North American drug product CDMO after emerging as a standalone contract development and manufacturing organization focused exclusively on drug product services in North America. The transition follows SK Capital Partners’ decision to divest the active...
Business & Industry
Drugmakers Turn to AI To Speed Up Trials and Submissions
Drugmakers turn to AI as a practical way to reduce delays in clinical trials and regulatory submissions, even as artificial intelligence has yet to consistently deliver breakthrough drug molecules, industry executives said at the JP Morgan Healthcare Conference.
Executives from...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















